Amit Anand MD

Published on 6/3/2024

Jha MK, Wilkinson ST, Krishnan K, Collins KA, Sanacora G, Murrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, Barnett B, Chang L, Costi S, Malone D, Nikayin S, Nissen SE, Ostroff R, Reti I, Wolski K, Wang D, Hu B, Mathew SJ, Anand A. Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024 Jun 03; 7(6):e2417786. PMID: 38916891.

Published on 12/1/2023

Mathew SJ, Jha MK, Anand A. Choosing Between Ketamine and Electroconvulsive Therapy for Outpatients With Treatment-Resistant Depression-Advantage Ketamine? JAMA Psychiatry. 2023 Dec 01; 80(12):1187-1188. PMID: 37878334.

Published on 9/7/2023

Anand A, Mathew SJ, Hu B. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. Reply. N Engl J Med. 2023 Sep 07; 389(10):961-962. PMID: 37672705.

Published on 5/24/2023

Anand A, Mathew SJ, Sanacora G, Murrough JW, Goes FS, Altinay M, Aloysi AS, Asghar-Ali AA, Barnett BS, Chang LC, Collins KA, Costi S, Iqbal S, Jha MK, Krishnan K, Malone DA, Nikayin S, Nissen SE, Ostroff RB, Reti IM, Wilkinson ST, Wolski K, Hu B. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. N Engl J Med. 2023 Jun 22; 388(25):2315-2325. PMID: 37224232.

Published on 3/29/2023

Niemsiri V, Rosenthal SB, Nievergelt CM, Maihofer AX, Marchetto MC, Santos R, Shekhtman T, Alliey-Rodriguez N, Anand A, Balaraman Y, Berrettini WH, Bertram H, Burdick KE, Calabrese JR, Calkin CV, Conroy C, Coryell WH, DeModena A, Eyler LT, Feeder S, Fisher C, Frazier N, Frye MA, Gao K, Garnham J, Gershon ES, Goes FS, Goto T, Harrington GJ, Jakobsen P, Kamali M, Kelly M, Leckband SG, Lohoff FW, McCarthy MJ, McInnis MG, Craig D, Millett CE, Mondimore F, Morken G, Nurnberger JI, Donovan CO, Øedegaard KJ, Ryan K, Schinagle M, Shilling PD, Slaney C, Stapp EK, Stautland A, Tarwater B, Zandi PP, Alda M, Fisch KM, Gage FH, Kelsoe JR. Focal adhesion is associated with lithium response in bipolar disorder: evidence from a network-based multi-omics analysis. Mol Psychiatry. 2024 Jan; 29(1):6-19. PMID: 36991131.

Published on 4/4/2022

Hu B, Cha J, Fullerton JM, Hesam-Shariati S, Nakamura K, Nurnberger JI, Anand A. Genetic and environment effects on structural neuroimaging endophenotype for bipolar disorder: a novel molecular approach. Transl Psychiatry. 2022 Apr 04; 12(1):137. PMID: 35379780.

Published on 3/14/2022

Tamman A, Anand A, Mathew SJ. A comparison of the safety, feasibility, and tolerability of ECT and ketamine for treatment-resistant depression. Expert Opin Drug Saf. 2022 Jun; 21(6):745-759. PMID: 35253555.

Published on 1/21/2022

Cha J, Spielberg JM, Hu B, Altinay M, Anand A. Differences in network properties of the structural connectome in bipolar and unipolar depression. Psychiatry Res Neuroimaging. 2022 Apr; 321:111442. PMID: 35152051.

Published on 1/7/2022

Cha J, Spielberg JM, Hu B, Altinay M, Anand A. Resting-state functional connectivity graph-properties correlate with bipolar disorder-risk in young medication-free depressed subjects: Bipolar-risk Resting State Functional Connectivity in Major Depression. J Affect Disord. 2022 Mar 15; 301:52-59. PMID: 35007643.

Published on 3/26/2021

Taylor JJ, Kurt HG, Anand A. Resting State Functional Connectivity Biomarkers of Treatment Response in Mood Disorders: A Review. Front Psychiatry. 2021; 12:565136. PMID: 33841196.